[ Search Options ]

Philip Wang, M.D., Dr.P.H.

Name, Degree: Philip Wang M.D., Dr.P.H.
Role(s) in Task Force and Work Group: DSM-V Task Force Member
Institutional Affiliation(s): National Institute of Mental Health
City, State: Rockville, MD

Biographical Sketch:

Philip S. Wang, M.D., Dr.P.H., is the Director of the Division of Services and Intervention Research at the National Institute of Mental Health. He also remains on leave from his faculty appointments in Psychiatry and Health Care Policy at Harvard Medical School. He completed his undergraduate, medical school, psychiatry residency, as well as doctoral training in epidemiology, all at Harvard University. His research has focused on three areas: psychopharmacoepidemiology; psychopharmacoeconomics; and mental health services research. He was the Principal Investigator of the NIMH-sponsored Work Outcomes Research and Cost-effectiveness Study (WORCS), a large-scale trial to examine the return-on-investment of enhanced depression care for workers. Dr. Wang has served as a voting member on the FDA Psychopharmacologic Drugs Advisory Committee, FDA Neurological Devices Panel, and FDA Endocrinologic and Metabolic Drugs Advisory Committee. He also served on the NIMH Services Research and Clinical Epidemiology Study Section. He is currently Chair of the WHO World Mental Health Study Services Research Work Group. He is a member of the American Psychiatric Association’s DSM-V Task Force and has consulted on several APA Work Groups to develop evidence-based treatment guidelines. Dr. Wang is an author of approximately 140 scientific publications.

Uncompensated affiliations with non-profit or advocacy organizations that may have a direct or indirect interest in psychiatric diagnosis, treatment, or the DSM-V : Three calendar years before nomination and Each year thereafter through the present calendar year. (For 2008, activities to date and commitments for remainder of year.)

Non-Profit and Advocacy Organizations	Year(s)	Role
None

The two tables below represent Dr. Wang’s disclosure of significant interests and affiliations for: (1) The time period including the 3 years prior to nomination to serve on the DSM-V Task Force; the calendar year in which nomination to the Task Force occurred; through the calendar year in which the nomination was approved; and (2) the time period including the calendar year after approval, and each successive year to the present.

Dr. Wang has agreed that, from the time of approval through the publication of DSM-V, projected in 2012, his aggregate annual income derived from industry sources (excluding unrestricted research grants) will not exceed $10,000 in any calendar year.

KEY NUMBER:
1. Consultation Fees (include scientific advisory boards)
2. Full- or Part-time Employee
3. Industry-related Grant-Research Support received or pending
4. Honoraria (includes Speakers’ Bureau)
5. Stock or other financial options

6. Expert testimony
7. Royalties (including right to share of revenue or profit from pharmaceutical, device or other development or product)
8. Patents received or pending
9. Officer, director/trustee, executive (specify)
10. Other (specify)

Disclosure of significant interests including: Three (3) calendar years before nomination, the calendar year of nomination, through the calendar year of approval to serve on the DSM-V Task Force

Commercial or Other Organization	Year(s)	Key #(s)
Phillips Lytle LLP (law firm representing GlaxoSmithKline)	2003-5	1
Innovus, Inc.	2003-5	1
Phillips Lytle LLP	2004-5	6
Collegium Internationale Psychopharmacologicum	2005	4

Disclosure of significant interests Beginning with the calendar year after APA Board of Trustees approval to serve on the DSM-V Task Force, to the present. (For 2008, activities to date and commitments for remainder of year.)